A month has gone by since the last earnings report for AngioDynamics (
ANGO Quick Quote ANGO - Free Report) . Shares have lost about 10.4% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is AngioDynamics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
AngioDynamics Q2 Earnings Beat Estimates, View Retained
AngioDynamics reported second-quarter fiscal 2020 adjusted EPS of 6 cents, which beat the Zacks Consensus Estimate of 2 cents. However, the bottom line dropped a significant 52.9% from the year-ago quarter.
Revenues of the company totaled $70 million, falling short of the Zacks Consensus Estimate of $71.9 million. The top line however inched up 0.03% on a year-over-year basis. Organically, revenues were flat year over year.
In the quarter under review, U.S. net revenues totaled $55.6 million, down 1.3% year over year and at constant currency (cc).
International revenues summed $14.4 million, up 5.6%. At cc, revenues rose 6.6%.
Segmental Analysis Vascular Interventions and Therapies (VIT) Business
VIT revenues in the second quarter grossed $31.2 million, up 0.6% from the year-ago quarter’s figure.
Per management, strong growth in AngioVac and core VIT product line drove revenues.
Vascular Access (VA) Business
Revenues at this segment amounted to $22.8 million, down 4% on a year-over-year basis. Per management, lower sales of Ports and PICCs impeded quarterly growth.
Revenues at the Oncology segment improved 5.1% year over year to $16.1 million. Per management, higher sales of NanoKnife and the Alatus and IsoLoc balloon products drove the upside.
In the quarter under review, gross profit totaled $41.5 million, up 2.4% from the year-ago quarter number. Also, gross margin was 59.3%, up 140 basis points (bps) primarily driven by productivity and supply chain improvement as well as positive product mix.
Research and development expenses were $7.8 million, up 9.7% year over year. Sales and marketing expenses totaled $19.4 million, up 4.4% on a year-over-year basis. General and administrative expenses were $11 million, up 18.7%.
For fiscal 2020, AngioDynamics continues to expect revenues in the $280-$286 million band.
The company expects EPS within 10-15 cents.
Gross margin is projected in the range of 58-59%.
Notably, AngioDynamics anticipates investments related to the product launches acquired from Eximo in the second half of fiscal 2020.
How Have Estimates Been Moving Since Then?
Estimates review followed a downward path over the past two months. The consensus estimate has shifted -50% due to these changes.
Currently, AngioDynamics has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. Charting a somewhat similar path, the stock was allocated a grade of B on the value side, putting it in the top 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
AngioDynamics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.